Jenoptik with sustained good demand from the semiconductor equipment industry and the public sector in first half-year

. – Group order intake down on prior year; order backlog slightly up – Adjusted revenue decreased by 11.9 percent to 329.0 million euros – Sharp improvement in second-quarter profitability (adjusted EBITDA margin up from 10.5% in Q1 to 15.6% in Q2) – Adjusted free cash flow up to 17.8 million euros – More precise Read more about Jenoptik with sustained good demand from the semiconductor equipment industry and the public sector in first half-year[…]

Defence remains an anchor of stability during coronavirus crisis

. – The Group’s half-year sales fall by 7.7% to €2,597 million due to declining automotive markets – Coronavirus crisis causes drop in consolidated operating earnings from €163 million to €70 million – Defence continues to grow: sales rise by 19% to €1,641 million; operating earnings improved by 75% to €122 million – Automotive significantly Read more about Defence remains an anchor of stability during coronavirus crisis[…]

RWE and Bosch sign long-term solar power purchase agreement

16-year 50-megawatt power purchase agreement Green electricity goes directly to German Bosch sites PPA model ensures construction of new solar farms in southern Germany RWE Supply & Trading will provide Bosch with solar power. The total volume amounts to 50 megawatts. The company will source the power from several new farms in southern Germany developed Read more about RWE and Bosch sign long-term solar power purchase agreement[…]

Interim Report First Half Year 2020

KUKA is feeling the effects of the coronavirus pandemic and the global economic crisis Customers are delaying investments and postponing planned orders Orders received, sales revenues and EBIT significantly below previous year’s level KUKA CEO Peter Mohnen: “Our focus is on setting the course for the future. Automation can come out of this crisis as Read more about Interim Report First Half Year 2020[…]

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.00 per share. The proceeds of the offering to Read more about Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock[…]

Fraport Group Interim Report – First Half 2020: Covid-19 Pandemic Leads to Sharp Revenue and Profit Decline

Traffic volumes reach the bottom of the trough in the second quarter  Revenue slumps by nearly 50 percent during the first half of 2020  Group result (net profit) clearly negative  Liquidity secured over the long term Impacted by the Covid-19 pandemic, the airport operator Fraport posted a sharp drop in revenue during the first half Read more about Fraport Group Interim Report – First Half 2020: Covid-19 Pandemic Leads to Sharp Revenue and Profit Decline[…]

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell 5 million shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant Read more about Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock[…]

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis  Statistically Significant Reduction of 62% and 70% in Combined Unique Active Magnetic Resonance Imaging Lesions in 45mg and 30mg Patient Cohorts, As Compared to Placebo  Data Supports Previously Observed Favorable Safety Profile of IMU-838 in Relapsing-Remitting Read more about Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis[…]

RWE to strengthen its European renewables business with acquisition of 2.7 GW project pipeline

Nordex has selected RWE as exclusive bidder for the acquisition of its European onshore wind and solar development business / Purchase price of about €400 million Strategic enhancement adds to RWE’s existing 22 GW development pipeline Expansion of position in attractive French onshore wind market Markus Krebber, CFO of RWE AG: ”The planned acquisition of Read more about RWE to strengthen its European renewables business with acquisition of 2.7 GW project pipeline[…]

Analog Devices, Inc. to Report Third Quarter Fiscal Year 2020 Financial Results on Wednesday, August 19, 2020

 Analog Devices, Inc. (Nasdaq: ADI) today announced it will release financial results for the third quarter fiscal year 2020 at 8 a.m. Eastern time on Wednesday, August 19, 2020. Following the press release, the Company will host a conference call at 10:00 a.m. Eastern time, the same day. Vincent Roche, President and Chief Executive Officer, Prashanth Mahendra-Rajah, Senior Vice President, Finance and Chief Read more about Analog Devices, Inc. to Report Third Quarter Fiscal Year 2020 Financial Results on Wednesday, August 19, 2020[…]